title: Trisomy 12 and p53 deletion in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: association with morphology and resistance to conventional chemotherapy.
abstract: The incidence of trisomy 12 and p53 deletion was studied in a group of chronic B-lymphocytic leukemia (B-CLL) patients, using fluorescence in situ hybridization (FISH). Trisomy 12 was detected in eight of 50 patients (16%) and p53 deletion in six of 38 cases analyzed (15.8%). A statistically significant difference was observed between the incidence of trisomy 12 in patients with typical and atypical morphology (3.03% versus 41.18%). No correlation was found between this alteration and the rest of the clinical and biological parameters studied (adenopathies, hepatomegaly, splenomegaly, lymphocyte count, staging, CD11c expression, and resistance to chemotherapy). The p53 deletion was correlated with the presence of hepatomegaly and splenomegaly, advanced stage of disease, and resistance to conventional chemotherapy. The application of FISH to whole blood cell nuclei, without prior manipulation or culture, showed a higher percentage of cells with trisomy 12 than when the method was used following culture. We conclude that 1) FISH is a simple and sensitive technique for the detection of numerical and structural chromosome abnormalities; 2) Its application to uncultured samples obviates the alteration of results originated by the probable growth advantage of the normal or neoplastic cell population in vitro; 3) Trisomy 12 appears to define a B-CLL subgroup of atypical morphology; and 4) The p53 deletion is correlated with advanced stage of disease and resistance to treatment.
authors.affiliation: Department of Hematology and Hemotherapy, Hospital La Paz, Madrid, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Cano
authors.forename: J
authors.initials: J
authors.lastname: Martinez
authors.forename: E
authors.initials: E
authors.lastname: Quevedo
authors.forename: J
authors.initials: J
authors.lastname: Pinilla
authors.forename: A
authors.initials: A
authors.lastname: Martin-Recio
authors.forename: A
authors.initials: A
authors.lastname: Rodriguez
authors.forename: A
authors.initials: A
authors.lastname: Castañeda
authors.forename: R
authors.initials: R
authors.lastname: López
authors.forename: T
authors.initials: T
authors.lastname: Pérez-Piño
authors.forename: F
authors.initials: F
authors.lastname: Hernández-Navarro
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002881:Chromosomes, Human, Pair 12; D003360:Cosmids; D003520:Cyclophosphamide / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D017353:Gene Deletion; D016158:Genes, p53; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007399:Interphase; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008214:Lymphocytes / Q000166:cytology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D012016:Reference Values; D015203:Reproducibility of Results; D012189:Retrospective Studies; D014314:Trisomy; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone